Standard Glass Lining Ltd.

About Standard Glass Lining

Incorporated in 2012, Standard Glass Lining Technology and its subsidiaries make specialized engineering equipment used mainly by pharmaceutical and chemical companies. Its products include glass-lined reactors, receivers and heat exchangers, alongside metal equipment, pumps and PTFE-lined pipes and fittings. The report describes 8 manufacturing facilities spread over 400,000 sq.ft., located in Hyderabad, Telangana, with sales offices in Gujarat, Maharashtra and Andhra Pradesh and pan-India reach.

Investment Rationale

• Revenue growth and margins: Revenue increased from INR 240 Cr. in FY22 to INR 544 Cr. in FY24. EBITDA margin rose from 16.8% to 17.4% over the same period and was 18.7% in 9M-FY25.
• Product range and launches: The company makes 72 types of products, with 18 more under development. Planned launches include shell and tube heat exchangers under a licensing agreement with AGI Inc., Japan, and glass for semiconductor applications.
• Strategic collaborations: Partnerships with HHV Pumps, Asahi Glassplant, GL Hakko and Gale Process Solutions support sourcing, product development and export sales. An agreement with BioCon Solutions Pte Ltd. covers exports to specified territories in Southeast Asia.
• Repeat business: Repeat customers contributed ~53.5% of FY24 revenue and 56.5% in H1FY25. Thirteen of the top 20 customers had relationships with the company lasting more than 3 years.
• Industry demand: The report expects opportunities from pharmaceutical and chemical sector capex and projects the India Glass Lined Equipment market to grow at a CAGR of 10.1% from FY2024-2029.

Standard Glass Lining Key Financials

Revenue growth accelerated to 31% in 9M-FY25, while the reported EBITDA and PAT margins were 18.7% and 11.5%, respectively.

Products, Capacity and Partnerships

The product portfolio covers reaction systems; storage, separation and drying systems; and plant, engineering and services. Glass lining coats steel and nickel-alloy equipment on surfaces that contact corrosive chemicals. The report highlights corrosion resistance, chemical stability, hygienic properties, versatility and thermal-shock resistance as benefits.

Manufacturing is spread across the company’s glass-lined equipment unit and subsidiary facilities for stainless steel and nickel-alloy equipment, pumps, heat exchangers, PTFE-lined pipes and fittings, and storage equipment. The report notes that an additional S2 unit was under construction and expected to be completed by end of Feb’25.

• Export development: S2 Engineering entered an exclusive, long-term supply and purchase agreement with Gale Process Solutions in March 2025 to sell products and expand export sales.
• New customer territories: An April 2025 agreement with BioCon Solutions provides for exports to customers in Singapore, Indonesia, Malaysia and Thailand.

Industry Outlook

The report links demand for the company’s equipment to investment in pharmaceutical and chemical industries. It says Indian pharmaceutical capex could increase to INR 120 Bn. and INR 150 Bn. per year up to FY27, supported by local and export demand and PLI or government policies. Chemical capex is expected to grow with demand for specialized chemicals and medicines, alongside other factors including supply-chain diversification.

Frost & Sullivan Analysis projects the India Glass Lined Equipment market to grow at a CAGR of 10.1% from FY2024-2029. The report also identifies growth opportunities across reactors, filters and dryers, vacuum pumps, high-alloy steel, PTFE-lined pipes and fittings, and heat exchangers.

Peer Position

The report compares Standard Glass Lining with GMM Pfaudler, HLE Glasscoat, Praj Industries, Thermax and BEW Engineering. Standard Glass Lining’s FY21-to-FY24 revenue CAGR was 62.4%; the report notes that the company delivered higher growth than its peers despite a capex slowdown in pharmaceutical and chemical sectors. It also identifies larger competitors, including GMM Pfaudler, as a constraint on pricing flexibility.

Valuation and Target Price

The report lists the CMP as INR 131.50/- as of 09-May’25 and the target price as Unrated. It gives the company a Positive outlook, not a Buy, Hold or Sell recommendation.

INR 131.50/-

CMP (09-May’25)

Unrated

Target price

Positive

Outlook

Key Risks

• Working capital and cash flow: Large raw-material and work-in-progress inventory and high debtor levels make operations working-capital intensive. Negative CFO may strain the company as it scales; positive CFO in coming years is a key monitorable.
• Competitive pressure: The presence of larger competitors may constrain pricing flexibility.
• End-market capex: A slowdown in capex in pharmaceutical and chemical industries could affect demand for the company’s equipment.
• Revenue expectations: Expected FY25 revenues of INR 650 Cr. and management guidance for future years remain key monitorables.

Our View

Minerva Capital Research Solutions gives Standard Glass Lining a Positive outlook, pointing to its record of growth ahead of peers, improving margins, capacity expansion, upgraded CRISIL ratings, industry tailwinds and strategic partnerships. Working-capital demands and the company’s ability to generate positive CFO remain central monitorables; the report does not assign a target price.

Standard disclosures

• Research Analyst has served as an officer, director or employee of subject company(ies): No
• We or our associates have received compensation from the subject company(ies) in the past 12 months: No
• We or our associates have managed or co-managed public offering of securities for the subject company(ies) in the past12 months: No
• We or our associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months –No
• We or our associates may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report –No
• We or our associates or Research Analyst or his/her relative's financial interest in the subject company(ies)- No
• Nature of financial interest in subject company, if any –Nil
• We, our associates or Research Analyst have actual/beneficial ownership of 1% or more securities of the subject company (ies) at the end of the month immediately preceding the date of publication of Research Report – No
• Subject company (ies) may have been client during twelve months preceding the date of distribution of the research report-No.
• We or our Associates or Research Analyst are engaged in market making of subject company – No
• By referring to any particular sector, Minerva Capital Research Solutions does not provide any promise or assurance of favorable view for a particular industry or sector or business group in any manner. The investor is requested to take into consideration all the risk factors including their financial condition, suitability to risk return profile and take professional advice before investing. Such representations are not indicative of future results.
• There are either no material conflict of interests or all existing and potential conflict of interest are disclosed herein.

Regulatory disclosures

Minerva Capital Research Solutions is an independent investment advisory firm founded by Nishant Gupta(SEBI registration no. INH000018896).

Registration granted by SEBI and certification from NISM in no way promise or guarantee that the research recommendation will provide any assured, minimum or risk-free return to the investors.

The research report serves as general information and does not account for individual investment goals, financial situations, or needs. Minerva Capital Research Solutions strives to provide reliable and comprehensive information, sourced from what are believed to be trustworthy channels. However, this information has not been independently verified by Minerva Capital Research Solutions or its analysts, and no guarantees are made regarding its accuracy or completeness. The opinions expressed in this report reflect the views of the research analyst at the time of publication and may change over time. Minerva Capital Research Solutions and its affiliates as on date of publication of this report may or may not hold any positions in the securities discussed. The views presented are general and do not consider individual risk tolerance or investment objectives; therefore, readers should seek independent professional advice before making investment decisions. Minerva Capital Research Solutions does not guarantee a favorable outlook for any specific industry or sector and urges investors to consider all relevant risk factors, including their financial circumstances, before investing. The analyst certifies that their views accurately represent their personal opinions on the companies discussed and that no part of their compensation is tied to specific recommendations made in this report. This material should not be interpreted as an offer or solicitation to buy or sell securities in jurisdictions where such offers would be illegal. Consequently, brokerage and investment services described herein are not available to Canadian or U.S. persons. Distribution outside India requires prior written consent. This Research Report assumes that the recipient will assume all risks associated with its contents. If there are any disagreements or dissatisfaction with this report or its disclaimer, the only recourse is to cease using it. Minerva Capital Research Solutions and its affiliates will not be liable for any direct or indirect losses resulting from the use of this report. Recipients are required to adhere to these restrictions. The material is for the personal use of authorized individuals and does not constitute a solicitation or offer to buy or sell any securities in jurisdictions where such actions would be illegal.

For any queries or grievances: Mr. Nishant Gupta | Email: nishant.gupta@mcapital.in | Contact Number: 8171433387 | Website: www.mcapital.in | Twitter: @Mcapital_In

Rating rationale

Minerva Capital Research Solutions endeavors to provide objective opinions and recommendations. Ratings are assigned to stocks according to their fair value vs current market price and then categorizes them as Buy, Hold, Reduce, Sell. The performance horizon is one year unless specified and fair value is defined as analyst’s valuation for a stock.

• Buy:> 15%
• Hold: -5% to 15%
• Reduce: -15% to -5%
• Sell: <-15%